Flagship · Bulletin

Macro rationale

NEUTRAL is unchanged and the cross-signals are genuine. Hawkish side: Warsh's Jackson Hole speech pushed September hike odds to 60%, the 10y real yield sits at 2.42%, and the digest tilts compute -2 and defense -3 on the rate shock; defense is also carrying a -7.4pp 1m lag vs SPY with the CR calendar throttling FY2027 obligation flow. Calm side: VIX 14.43 (-21.2% vs 200d), HY-OAS ~3, breadth 63% of sectors above their 50d, SPY/QQQ firm above their 200d. Rotation says risk appetite is intact but narrow-ish — XBI +7.86pp and XLK +3.68pp lead, XLU -7.46pp and ITA -7.4pp lag, equal-weight -0.64pp vs SPY. That is neither a risk-on breakout nor a credit/vol break, so the regime call holds and the cash band does the de-risking. Cash: the extension escalator is live (QQQ +8.99% vs its 200d), which lifts the NEUTRAL ceiling to 25%; the §5.4 working reserve is enforced at 17%. I carried 21.91% and I am deploying the deployable 4.9pp down to exactly the 17.01% reserve line — not a regime change, a named funding of two opens I have now committed three runs running and failed to land twice. The floor of the band is untouched and I am not raising cash on a hawkish headline. Hedges stay at baseline, not max: SCCO RSI 59 and NEM RSI 61 are mid-range, gold at ~$4,700 after a 14% August is the stagflation hedge working, and copper's $20.5B Grupo Mexico investment plan confirms the deficit thesis. No escalation to max hedging is warranted with VIX at 14.4.

Thesis

Two tickets, both the foundation build I have journaled for four runs and executed zero times. Everything else is a verbatim hold at entry weight, delta 0. The trigger — NVS +6.59% on positive Phase III remibrutinib data in relapsing MS — is on-thesis confirmation, not a break. Remibrutinib is exactly the "diversified in-market cash flow plus a pipeline that is addition, not subtraction" case I underwrote nine days ago. The briefer flags NVS and BEAM "broken" on score (51 and 43), but both entered AT those scores by deliberate design — NVS on a durable_value basis, BEAM as a §2 growth-starter — so a score that did not move is not new information. Both are 9 days old and locked; closing either now is precisely the fast-reversal churn this book exists to avoid. Hold both, unchanged. The real work: cash was 21.91% with the foundation sleeve empty and the mirror flagging it. The 17% working reserve caps deployment at 4.9pp, so I size to fit rather than repeating a 7pp intent that gets shrunk. CINF 2.5% (score 79, 8.4x P/E, 20% ROIC, 0.05x D/E, 65-year dividend-increase streak) and V 2.4% (50.2% FCF margin, 64.7% ROIC) — both dossier-backed (8/06, 26d), both regime-indifferent, both non-AI. AI-load unchanged at 25.65%, compute 21.78%, no cap moves, no theme above 40%. Mid-cap sleeve, names actually considered and rejected: NTLA (flow 70, but $1.7B pre-revenue on a binary FDA decision — clears the catalyst bar, fails the durability bar); SK ADR (real HBM bottleneck but an OTC AD

Reflection

NVS remibrutinib Phase III is pipeline confirmation, not a break — zero funder reversals book-wide again. The only real work was finally landing the foundation build, sized to the 17% reserve.

Third run committing CINF/V and the first where I sized them to what the working reserve actually permits (4.9pp, not 7pp) — I suspect my two failed builds were refused for breaching the reserve, not lost. Sizing to the mechanical constraint instead of to intent is the fix. Second: the briefer called NVS and BEAM 'broken' on scores that have not moved one point since I opened them at those scores nine days ago. A score that entered below 60 by design and stayed there is not new information — but I should notice that I am now carrying two positions whose only defence is 'I knew that when I boug

Positions (16)

• MUMicron Technologycompute

  hold3.76%87
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise: 84.6% gross margin, FCF positive, and after two decades of cycle abuse a three-player HBM oligopoly that is finally capacity-disciplined and pre-sold. Named flow: 16 Strategic Customer Agreements worth ~$100B of contracted multi-year supply; NVDA's 8/27 disclosure of $279B in supply commitments (doubled) IS a memory purchase line; HBM4 targeting 2

  Unwind

  Erosion of the 14-16 SCA contract book or customer deposits being returned; HBM oversupply as new 2027 capacity lands; a named hyperscaler capex cut; gross margin breaking back below 40% on a pricing reset.

  Catalyst

  Fiscal Q4 earnings Sept 30 — ~$50B revenue / ~$31 EPS guided; watch HBM bookings and 2027 contract coverage.

  Scenarios · 12mo targets

  $1,100.00 base

  $1,400.00 bull — HBM4 lands at 22-23% share into a supply-constrained 2027, SCA book extends past 2028, and memory pricing power persists as NVDA absorbs the cost.

  $700.00 bear — 2027 capacity from all three players lands together, HBM pricing resets, and the cycle discipline that justified the re-rating breaks.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.67%86
  flow acceleratingconf

  Funder

  Effective foundry monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry and ~90% advanced-node share, and a management culture that has out-executed Intel and Samsung for a decade. Named flow: 2026 capex guided to $60-64B; CoWoS booked out through end-2026 with NVIDIA taking ~60%; CHIPS $6.6B Arizona disbu

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or a 2027 capex guide cut signalling the AI order book rolling over.

  Catalyst

  Monthly revenue prints and the October Q3 call with 2027 capex framing; CoWoS outsourcing ramp confirmation to Amkor/ASE.

  Scenarios · 12mo targets

  $500.00 base

  $620.00 bull — 2027 capex guide steps up again on N2 demand, CoWoS expansion to 115-140 KWPM sells out, and advanced-node pricing holds >55% gross margin.

  $330.00 bear — Hyperscalers digest 2026 orders, N2 ramp costs compress margin below 50%, or a Taiwan geopolitical shock reprices the whole franchise.

• NVDANVIDIAcompute

  hold3.51%74
  flow acceleratingconf

  Funder

  AI-accelerator franchise with the CUDA software moat — 75% gross margin, fortress balance sheet, and developer lock-in no ASIC rival has replicated in a decade. Named flow: the 8/27 Q2 print of $96.2B revenue (+106% YoY), FY28 guidance implying ~70% growth against ~44% consensus, and $279B of supply commitments (doubled) — read against my own unwind condition that is confirmation, not a break. Hyp

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; gross margin breaking below the guided 71-72% floor because memory cost cannot be passed through; hyperscalers converting a named large footprint to in-house ASIC; or a compute export-control action removing a material revenue block.

  Catalyst

  Next quarterly print and any Rubin platform tape-out/shipment update; watch whether the 71-72% GM floor guided for Q4 FY28 holds.

  Scenarios · 12mo targets

  $260.00 base

  $330.00 bull — Rubin ramps into the doubled supply book, FY28 ~70% growth is delivered, and memory cost is passed through with GM holding above 72%.

  $155.00 bear — Memory cost compresses GM below the guided floor while ASIC in-sourcing at a named hyperscaler slows data-center growth toward 20%.

• ASMLASML Holdingcompute

  hold2.88%62
  flow steadyconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, with no commercial-scale alternative at 2nm, a multi-year backlog, ~50% gross margin, and an installed-base service annuity that earns through downturns. Named flow: 2026 revenue guided $36-40B on 60 low-NA EUV shipments (+25% units) with High-NA entering high-volume manufacturing; TSMC's $60-64B capex and Micron's $20B

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; or a credible non-EUV patterning path reaching production scale.

  Catalyst

  Q3 bookings print — the only number that resolves the score drift; High-NA HVM milestone confirmations at TSMC/Intel.

  Scenarios · 12mo targets

  $1,950.00 base

  $2,400.00 bull — 2026 shipments hit the 60-unit plan, High-NA orders convert, and the $36-40B guide is raised on the 2nm ramp.

  $1,250.00 bear — Bookings stay soft for a third quarter or an export-control tightening carves China service/tool revenue out of the backlog.

• AVGOBroadcomcompute

  hold2.84%63
  flow acceleratingconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software lock-in — 69.5% gross margin, huge FCF, $7B+ annual buyback, a serial dividend grower, and Hock Tan's capital-allocation record. Named flow: Alphabet TPU multi-generation, Meta MTIA, and the Anthropic 3.5GW ASIC program; guided ~$16B AI semiconductor revenue for the Sept 2 print at 200%+ YoY. Citadel's 11% Q2 trim is p

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise across multiple accounts (not one); or VMware renewal churn breaking the software annuity.

  Catalyst

  Q3 earnings Sept 2 — $16B AI revenue guide and the FY27 ASIC bookings commentary.

  Scenarios · 12mo targets

  $450.00 base

  $560.00 bull — Sept 2 confirms $16B AI revenue with 200%+ growth and a fourth named ASIC customer, while VMware renewals hold pricing.

  $280.00 bear — Alphabet moves TPU design in-house or the Anthropic program slips, stalling AI silicon below a $25B run-rate.

• ANETArista Networkscompute

  hold2.53%65
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, ~45% GAAP operating margin, zero debt, and the single-image EOS software moat that makes rip-and-replace expensive. Named flow: Microsoft and Meta named as largest customers funding record $3B quarterly revenue; the AI back-end ethernet build is the direct capex line; consensus 22 of 25 Strong B

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; or gross margin breaking below 60% on price competition.

  Catalyst

  Next quarterly print and any named hyperscaler back-end award moving to NVIDIA Spectrum-X.

  Scenarios · 12mo targets

  $230.00 base

  $290.00 bull — AI back-end ethernet share holds against Spectrum-X, revenue growth stays ~30%+, and margins hold at 45% operating.

  $145.00 bear — NVIDIA wins a named hyperscaler back-end away from EOS and customer concentration turns into pricing pressure.

• GEVGE Vernovaenergy

  hold5.76%61
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — heavy-duty turbines effectively sold out through 2030, 10-20% price realization on new orders, and an installed-base service annuity that is the real profit engine. Named flow: $176B backlog with 88% order growth; DOE projecting ~100GW of new grid capacity needed by 2030 with roughly half from data centers; Norway GPFG added post-spin; Ch

  Unwind

  Gas-turbine backlog cancellation or a named hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or the order book ceasing to convert to revenue at the guided cadence.

  Catalyst

  Next backlog/order disclosure and any named data-center power PPA cancellation; RSI 35 says the AI-commitments scare is in the price.

  Scenarios · 12mo targets

  $1,050.00 base

  $1,300.00 bull — Backlog converts on schedule, turbine pricing holds 10-20% realization, and the wind drag turns to breakeven as the grid segment scales.

  $650.00 bear — A genuine hyperscaler power-capex pause cancels turbine slots and wind losses keep consuming gas-segment profit.

• SCCOSouthern Copperenergy

  hold9.72%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive with a large dividend, and Grupo Mexico control enforcing capital discipline through the cycle. Named flow: the $20.5B investment plan announced 8/27 with a 1.6M-tonne target by 2033-34 confirms Tía María, Los Chancas and Michiquillay are advancing — the permitt

  Unwind

  Copper price collapse breaking the deficit thesis; Tía María / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican fiscal or nationalization shock.

  Catalyst

  Tía María construction milestones and Q3 production; full-year guidance was raised to 917k tonnes despite H1 -3.8% on ore grade.

  Scenarios · 12mo targets

  $235.00 base

  $290.00 bull — Copper deficit persists, Tía María reaches first production on schedule, and the $20.5B plan de-risks the path to 1.6M tonnes.

  $155.00 bear — A China-led demand air pocket collapses copper, or Peruvian permitting reverses again and the growth plan stalls.

• NEMNewmont Corporationenergy

  hold6.41%83
  flow acceleratingconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: gold +14% in August to ~$4,700/oz, $4.21B of weekly precious-metals fund inflows, and Treasury buyback operations compressing long yields — precisely the frozen-Fed stagflation bid this slot exists

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or the Fed pivoting decisively to cuts with inflation contained.

  Catalyst

  Sept 15-16 FOMC — a hike that convinces the market inflation is contained is the hedge's invalidation; next quarterly AISC print.

  Scenarios · 12mo targets

  $140.00 base

  $175.00 bull — Stagflation persists, central-bank and ETF gold accumulation continues past $4,700, and AISC discipline converts price into FCF and dividends.

  $90.00 bear — Warsh hikes and inflation breaks convincingly lower, real yields surge, and gold gives back the August move while costs creep.

• KTOSKratos Defensedefense

  hold11.41%64
  flow steadyconf

  Funder

  Scarce non-prime supplier of attritable airframes (XQ-58A Valkyrie), hypersonics and turbine engines, with a decade of embedded program positions the primes cannot easily displace and vertical propulsion capability almost no competitor owns. Named flow: DoD MACH-TB 2.0 $1.45B IDIQ ceiling, Project Helios, USMC Valkyrie mods, a fresh $35M military-hardware production award, and the FY27 DAWG $54.6B

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut; or an FY2027 appropriation that guts the DAWG line.

  Catalyst

  FY2027 appropriations / CR resolution (Dec 4 deadline) and the next earnings print on revenue scale plus margin inflection — the entry trigger I still need verified.

  Scenarios · 12mo targets

  $60.00 base

  $78.00 bull — Valkyrie and hypersonics production scale, margins inflect positive on FCF, and the DAWG line funds a multi-year attritable-airframe ramp.

  $35.00 bear — CR funding at prior-year levels delays new starts, the drone ramp stays FCF-negative, and a 95x forward multiple de-rates hard.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF above 20% through disciplined tuck-in acquisitions funded from cash flow, on 41.1% gross margin with PMA parts economics the OEMs cannot easily attack. Named flow: Q2 beat both segments (FSG $929M vs $864M, ETG $460M vs $396M), NDAA mandatory funding, and

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the tuck-in discipline; or forward P/E above 50x AT decelerating growth — the multiple leg is live at ~54x, the growth leg is not.

  Catalyst

  Next quarterly print — the specific test is whether organic growth decelerates below 6% while the multiple stays above 50x; both legs must fire.

  Scenarios · 12mo targets

  $375.00 base

  $450.00 bull — Organic growth stays double-digit, tuck-ins keep compounding FCF above 20%, and the aftermarket cycle extends through the CR drag.

  $250.00 bear — One guidance cut trips both invalidation legs at once — sub-6% organic growth at a 54x multiple de-rates violently.

• LLYEli Lillybiology

  hold4.94%74
  flow steadyconf

  Funder

  Premier pharma compounder — the tirzepatide franchise on 85.8% gross margin plus a manufacturing moat from the $27B capacity build rivals cannot replicate quickly, run by a team with a genuine record of converting R&D into approved franchises. Named flow: FDA approval (8/31) of Mounjaro's cardiovascular-risk indication expands the reimbursed population; orforglipron already approved; retatrutide P

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; or IRA/MFP negotiation reaching the GLP-1 class on terms that break pricing.

  Catalyst

  Retatrutide Phase 3 readouts and Novo's oral Wegovy launch data — the script-share series is the number that matters, not the concentration headline.

  Scenarios · 12mo targets

  $1,300.00 base

  $1,600.00 bull — Retatrutide delivers on safety, the CV label broadens reimbursement, and the $27B capacity build converts backlog into revenue at 85% gross margin.

  $850.00 bear — Novo's oral takes >5pts of US script share over two quarters while MFP negotiation reaches the GLP-1 class — 67% revenue concentration cuts both ways.

• VRTXVertex Pharmaceuticalsbiology

  hold4.11%82
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine on 85.3% gross margin with a fortress net-cash balance sheet — profitable, so it is insulated from the rate vise that makes the biology pillar underweight. Named flow: Sionna Therapeutics' CF candidate failed its trial in August, extending the monopoly and patent exclusivity into the late 203

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value; or forward P/E pushing toward the 30x invalidation without pipeline conversion.

  Catalyst

  Suzetrigine (Journavx) launch traction and Casgevy reimbursement conversion; next quarterly CF revenue print.

  Scenarios · 12mo targets

  $640.00 base

  $780.00 bull — Alyftrek conversion holds CF revenue, suzetrigine builds a real non-opioid pain franchise, and Casgevy reimbursement finally scales.

  $440.00 bear — Non-CF pipeline fails to convert, the Crinetics deal destroys value, and the multiple compresses as CF growth flattens.

• ARGXargenxbiology

  hold4.03%69
  flow steadyconf

  Funder

  The Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, commercial-stage, high-margin and net cash, so it does not depend on capital markets in a 2.42% real-yield world. Named flow: FDA expanded gMG approval to all serotypes; Sanofi's CIDP rival trial failed, clearing competitive space; positive myositis and Sjogren's data; the

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share; or the Forte deal turning into an integration write-down.

  Catalyst

  Myositis and Sjogren's registrational readouts; quarterly Vyvgart net-revenue trajectory and Hytrulo conversion rate.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,500.00 bull — Myositis and Sjogren's convert to approvals, Hytrulo subcutaneous conversion accelerates the franchise, and FB102 validates the pipeline engine.

  $800.00 bear — A registrational indication fails or a rival FcRn takes measurable gMG share, and the Forte deal becomes a write-down.

• NVSNovartis AGbiology

  hold2.62%51
  flow acceleratingconf

  Funder

  Top-5 global pharma with genuinely diversified in-market cash flow — Kisqali, Scemblix, Leqvio, Fabhalta, Cosentyx — on ~40% core operating margin and strong FCF, run by a management team whose capital-allocation record is subtraction (Alcon, Sandoz spins) rather than empire-building. Named flow (this run's trigger): positive Phase III remibrutinib data in relapsing MS showing superiority over com

  Unwind

  Scale-in to ~5% requires two consecutive quarters of >=6% cc growth with core margin >=40%. Kill criteria: core margin below 35%, group revenue turning negative on the Entresto/Tasigna LOE cliff without pipeline offset, or a value-destroying large acquisition breaking the allocation record.

  Catalyst

  Remibrutinib MS regulatory filing timeline; next quarterly print — the >=6% cc growth with >=40% core margin test that scales this to 5%.

  Scenarios · 12mo targets

  $185.00 base

  $215.00 bull — Remibrutinib files and launches into the MS market while Kisqali/Scemblix growth covers the Entresto LOE — the >=6% cc growth test clears twice.

  $135.00 bear — The Entresto/Tasigna LOE cliff outruns the pipeline, core margin slips below 35%, and the growth-per-multiple case evaporates.

• BEAMBeam Therapeutics Inc. Common Stockbiology

  hold1.31%43
  flow steadyconf

  Funder

  Origin platform for base editing (David Liu science, Broad-licensed): single-base correction without double-strand breaks — the most differentiated editing chemistry in the field — with ~$1.21B cash funding BEAM-302 in AATD into 2028, so it does not need the capital markets in a 2.42% real-yield world. Named flow: BEAM-302 dosing completed with data selected for presentation; BEAM-101 tied second

  Unwind

  Kill immediately on any grade 3+ hepatotoxicity or off-target signal in BEAM-302/301 (the Verve-101 precedent), on a discounted equity raise before the AATD pivotal, or on the cash runway falling below 24 months.

  Catalyst

  BEAM-302 AATD dose-escalation data presentation at the September investor conference — the binary that scales or kills this starter.

  Scenarios · 12mo targets

  $42.00 base

  $75.00 bull — BEAM-302 shows durable AAT correction with clean liver safety, validating in-vivo base editing and pulling forward a pivotal plus partnership economics.

  $12.00 bear — A grade 3+ hepatotoxicity or off-target signal repeats the Verve-101 precedent and the platform premium evaporates before revenue exists.

Warnings

• §2 cap applied: KTOS
• §5.4 dry-powder: cash_pct 17.01% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)
• cash_band: final cash 18.27% above neutral base band top 15% (escalator active: extension; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)
• buy guard dropped 2 open(s): CINF, V (§3/§4/§6.3)

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.